Simone Minasi1,2, Caterina Baldi2, Francesca Gianno1,3, Manila Antonelli1, Anna Maria Buccoliero4, Torsten Pietsch5, Maura Massimino6, Francesca Romana Buttarelli7,8. 1. Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy. 2. Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. 3. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. 4. Pathology Unit, Meyer Children's University Hospital, I-50139, Florence, Italy. 5. Institute of Neuropathology, DGNN Brain Tumour Reference Centre, University of Bonn Medical Centre, Bonn, Germany. 6. Paediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 7. Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy. francesca.buttarelli@uniroma1.it. 8. Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. francesca.buttarelli@uniroma1.it.
Abstract
PURPOSE: The maintenance of telomere length prevents cancer cell senescence and occurs via two mutually exclusive mechanisms: (a) reactivation of telomerase expression and (b) activation of alternative lengthening of telomeres (ALT). ALT is frequently related to alterations on ATRX, a chromatin-remodelling protein. Recent data have identified different molecular subgroups of paediatric high-grade glioma (pHGG) with mutations of H3F3A, TERTp and ATRX; however, differences in telomere length among these molecular subgroups were not thoroughly examined. METHODS: We investigated which genetic alterations trigger the ALT mechanism in 52 IDH-wildtype, 1p/19q-wildtype pHGG. Samples were analysed for telomere length using Tel-FISH. ATRX nuclear loss of expression was assessed by IHC, H3F3A and TERTp mutations by DNA sequencing, and TERTp methylation by MS-PCR. RESULTS: Mutant H3.3 was found in 21 cases (40.3%): 19.2% with K27M mutation and 21.1% with G34R mutation. All H3.3G34R-mutated cases showed the ALT phenotype (100%); on the opposite, only 40% of the H3.3K27M-mutated showed ALT activation. ATRX nuclear loss was seen in 16 cases (30.7%), associated sometimes with the G34R mutation, and never with the K27M mutation. ATRX nuclear loss was always related to telomere elongation. TERTp C250T mutations were rare (5.4%) and were not associated with high intensity Tel-FISH signals, as TERTp hyper-methylation detected in 21% of the cases. H3.3/ATRX/TERTp-wildtype pHGG revealed all basal levels of telomere length. CONCLUSION: Our results show a strong association between H3.3 mutations and ALT, and highlight the different telomeric profiles in histone-defined subgroups: H3.3-G34R mutants always trigger ALT to maintain telomere length, irrespective of ATRX status, whereas only some H3.3-K27M tumours activate ALT. These findings suggest that acquiring the gly34 mutation on H3.3 might suffice to trigger the ALT mechanism.
PURPOSE: The maintenance of telomere length prevents cancer cell senescence and occurs via two mutually exclusive mechanisms: (a) reactivation of telomerase expression and (b) activation of alternative lengthening of telomeres (ALT). ALT is frequently related to alterations on ATRX, a chromatin-remodelling protein. Recent data have identified different molecular subgroups of paediatric high-grade glioma (pHGG) with mutations of H3F3A, TERTp and ATRX; however, differences in telomere length among these molecular subgroups were not thoroughly examined. METHODS: We investigated which genetic alterations trigger the ALT mechanism in 52 IDH-wildtype, 1p/19q-wildtype pHGG. Samples were analysed for telomere length using Tel-FISH. ATRX nuclear loss of expression was assessed by IHC, H3F3A and TERTp mutations by DNA sequencing, and TERTp methylation by MS-PCR. RESULTS: Mutant H3.3 was found in 21 cases (40.3%): 19.2% with K27M mutation and 21.1% with G34R mutation. All H3.3G34R-mutated cases showed the ALT phenotype (100%); on the opposite, only 40% of the H3.3K27M-mutated showed ALT activation. ATRX nuclear loss was seen in 16 cases (30.7%), associated sometimes with the G34R mutation, and never with the K27M mutation. ATRX nuclear loss was always related to telomere elongation. TERTpC250T mutations were rare (5.4%) and were not associated with high intensity Tel-FISH signals, as TERTp hyper-methylation detected in 21% of the cases. H3.3/ATRX/TERTp-wildtype pHGG revealed all basal levels of telomere length. CONCLUSION: Our results show a strong association between H3.3 mutations and ALT, and highlight the different telomeric profiles in histone-defined subgroups: H3.3-G34R mutants always trigger ALT to maintain telomere length, irrespective of ATRX status, whereas only some H3.3-K27Mtumours activate ALT. These findings suggest that acquiring the gly34 mutation on H3.3 might suffice to trigger the ALT mechanism.
Entities:
Keywords:
Alternative lengthening of telomeres; H3.3; Paediatric high-grade gliomas; Telomeres; pHGG
Authors: Kunitoshi Chiba; Franziska K Lorbeer; A Hunter Shain; David T McSwiggen; Eva Schruf; Areum Oh; Jekwan Ryu; Xavier Darzacq; Boris C Bastian; Dirk Hockemeyer Journal: Science Date: 2017-08-17 Impact factor: 47.728
Authors: Pedro Castelo-Branco; Sanaa Choufani; Stephen Mack; Denis Gallagher; Cindy Zhang; Tatiana Lipman; Nataliya Zhukova; Erin J Walker; Dianna Martin; Diana Merino; Jonathan D Wasserman; Cynthia Elizabeth; Noa Alon; Libo Zhang; Volker Hovestadt; Marcel Kool; David T W Jones; Gelareh Zadeh; Sidney Croul; Cynthia Hawkins; Johann Hitzler; Jean C Y Wang; Sylvain Baruchel; Peter B Dirks; David Malkin; Stefan Pfister; Michael D Taylor; Rosanna Weksberg; Uri Tabori Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak Journal: Cell Date: 2016-01-28 Impact factor: 41.582
Authors: Carla Danussi; Promita Bose; Prasanna T Parthasarathy; Pedro C Silberman; John S Van Arnam; Mark Vitucci; Oliver Y Tang; Adriana Heguy; Yuxiang Wang; Timothy A Chan; Gregory J Riggins; Erik P Sulman; Frederick F Lang; Chad J Creighton; Benjamin Deneen; C Ryan Miller; David J Picketts; Kasthuri Kannan; Jason T Huse Journal: Nat Commun Date: 2018-03-13 Impact factor: 14.919
Authors: Jacqueline A Brosnan-Cashman; Ming Yuan; Mindy K Graham; Anthony J Rizzo; Kaylar M Myers; Christine Davis; Rebecca Zhang; David M Esopi; Eric H Raabe; Charles G Eberhart; Christopher M Heaphy; Alan K Meeker Journal: PLoS One Date: 2018-09-18 Impact factor: 3.240
Authors: Alexandre de Nonneville; Sébastien Salas; François Bertucci; Alexander P Sobinoff; José Adélaïde; Arnaud Guille; Pascal Finetti; Jane R Noble; Dimitri Churikov; Max Chaffanet; Elise Lavit; Hilda A Pickett; Corinne Bouvier; Daniel Birnbaum; Roger R Reddel; Vincent Géli Journal: EMBO Mol Med Date: 2022-08-03 Impact factor: 14.260
Authors: Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639